Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
AgomAb Therapeutics NV (AGMB) had Free Cash Flow of -58.54M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-87.68M |
|
-- |
|
-- |
|
67.06M |
|
-67.06M |
|
-3.70M |
|
-70.77M |
|
-70.77M |
|
-70.77M |
|
-70.77M |
|
-70.77M |
|
-70.77M |
|
-67.06M |
|
-66.82M |
|
0.54M |
|
0.54M |
|
-162.04 |
|
-162.04 |
|
| Balance Sheet Financials | |
137.17M |
|
0.57M |
|
36.74M |
|
173.90M |
|
21.03M |
|
1.14M |
|
4.77M |
|
25.80M |
|
148.10M |
|
115.61M |
|
148.10M |
|
0.54M |
|
| Cash Flow Statement Financials | |
-58.54M |
|
-37.34M |
|
-0.38M |
|
193.99M |
|
97.77M |
|
-96.22M |
|
6.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.52 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
-58.54M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-47.78% |
|
-61.21% |
|
-40.69% |
|
-47.42% |
|
273.69 |
|
-108.19 |
|
-108.18 |
|